The goal of this clinical trial is to test in height increment of alveolar bone and safety evaluation index.

The main question it aims to answer are:

• The safety and effectiveness of magnesium calcium silicate three-dimensional alveolar bone repair unit in the repair of periodontal bone defects Participants will be treated through Guided Bone Regeneration operation with calcium magnesium silicate three-dimensional alveolar bone repair unit.

Inclusion Criteria:

• Age 18-65 years old, healthy;
• Good oral hygiene, do not smoke;
• There is bone defect at the tooth extraction site, and it is planned to carry out implant repair after tooth extraction;
• There is at least one healthy adjacent tooth in the mesial and distal surface of the tooth extraction site;
• The residual height from the bottom of the extraction socket to the crest of the alveolar ridge is ≥ 3 mm, with at least one bone wall;
• Can understand the purpose of the trial
• Be willing to cooperate with surgical treatment and follow-up, voluntarily participate in the trial
• Sign the informed consent form.

Exclusion Criteria:

• The affected tooth is in the acute inflammatory stage;
• Those who have bad habits such as smoking and drinking；
• Subjects who cause artifacts in oral imaging examination, such as the extraction site and its adjacent teeth are metal Dentures, porcelain teeth;
• Patients are allergic to ceramic implants;
• Those who have participated in other clinical trials in the past 3 months;
• The investigator estimated that the compliance was poor, or there were other factors that were not suitable for the test;
• Patients with a history of diabetes or abnormal blood glucose detection (fasting blood glucose ≥ 7mmol/L);
• Abnormal liver and kidney function (AST, ALT, creatinine ≥ 1.5 times ULN);
• Patients with serious endocrine and metabolic diseases;
• Have a history of tertiary hypertension;
• Have a history of osteoporosis;
• Those who are not suitable for surgery due to the history of malignant tumor or other serious diseases;
• People with a history of autoimmune diseases;
• Pregnant or lactating women;
• Mental disorders without autonomous behavior ability;
• Patients who are using steroids that interfere with calcium metabolism within 3 months before the signing of informed consent